The company said it will use the proceeds for various purposes, including working capital, capital expenditures, stock repurchases, dividends, and acquisitions.
The company took out the credit in connection with its $4.2 billion pending acquisition of electron microscopy firm FEI.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.
The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.
The company said the draw down is to provide working capital to use on a temporary basis.
The London-based firm plans to fund development and clinical trials for its point-of-care diagnostic test for serious blood infections.
The company replaced an existing $2.5 billion facility with an amended and restated $4 billion facility and entered into a new $7 billion facility.
The firm used about $1.68 billion of proceeds from the new term loans to repay existing secured credit facilities and transaction expenses.
The aggregate commitments for a credit facility reached in September was previously $400 million.
Along with the increase in the amount of the credit facility, its maturity was extended by more than two years to April 1, 2019.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.